Company Profile
A clinical-stage biotech developing novel psychedelic- and cannabinoid-inspired neurological medicines, with a pipeline aimed at anxiety, depression, and cancer-related psychological distress.
Rank #35
ENVB
$1.27
-5.22% (24h)
Last updated: 1 second ago
Market Cap
$5.12M
Volume (24h)
82.55K
Last Close (7D)
$1.27
A clinical-stage biotech developing novel psychedelic- and cannabinoid-inspired neurological medicines, with a pipeline aimed at anxiety, depression, and cancer-related psychological distress.
52-Week Range